Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BFRI - Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upsoide

BFRI - Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upsoide

Biofrontera Inc.
Shares of Bioferontera (BFRI +147.1%) have skyrocketed today after Roth Capital initiated the stock with a buy rating and a $20 price target (~660% upside). Analyst Jonathan Aschoff says his rating and target is based on future revuenue for Ameluz (aminolevulinic acid) and Xepi (ozenoxacin) cream for, respectively, actinic keratosis and impetigo. The company also markets BF-RhodoLed, and LED lamp emitting red light that is used in combination with Ameluz actinic keratosis. Biofrontera priced its October IPO at $18/share.

For further details see:

Recently IPOd Biofrontera surges 146% following Roth buy initiation; sees 660% upsoide
Stock Information
Company Name: Biofrontera Inc.
Stock Symbol: BFRI
Market: NASDAQ
Website: biofrontera-us.com
Menu
BFRI BFRI Quote BFRI Short BFRI News BFRI Articles BFRI Message Board
Get BFRI Alerts

News, Short Squeeze, Breakout and More Instantly...